Skip to content

Canagliflozin in non diabetic proteinuric disease

To assess the effect of canagliflozin in non diabetic proteinuric disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027679
Enrollment
100
Registered
2020-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N08- Glomerular disorders in diseases classified elsewhere

Interventions

Intervention1: Canagliflozin arm: To receive canagliflozin 100 mg per day. Patients diagnosed as glomerulonephritis on the basis of renal biopsy and having proteinuria 1 gm/day Should have e GFR 25

Sponsors

COMMAND HOSPITAL AIR FORCE BANGALORE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient in age group 18 to 75 years, registered in Nephrology OPD and was diagnosed as glomerulonephritis on the basis of renal biopsy and having proteinuria > 1 gm/day Should have e GFR > 25 ml/min/1.73 m2 The patient should be on a stable dose of an ACEi or ARB/immunosuppression for at least 4 weeks prior to randomization

Exclusion criteria

Exclusion criteria: Patient detected to be diabetic prior to enrolment or during the study Patient lost to follow up during the study period Patient whose baseline and follow up laboratory investigations, 24 hr urine protein, detailed renal biopsy report not available

Design outcomes

Primary

MeasureTime frame
Change in 24 hr proteinuria with canagliflozin for six weeks relative to no canagliflozin in patients with non diabetic kidney disease and proteinuria 1 gm/day on standard of care treatment(ACEI/ARB and immunosuppression if indicated)Timepoint: Change in 24 hr proteinuria with canagliflozin for six weeks relative to no canagliflozin in patients with non diabetic kidney disease and proteinuria 1 gm/day on standard of care treatment(ACEI/ARB and immunosuppression if indicated)

Secondary

MeasureTime frame
i. Effect of canagliflozin 100 mg/day compared to no canagliflozin on eGFR using EPI equation ii. Compare the effect of canagliflozin 100 mg/day on proteinuria of different aetiologies Timepoint: 6 months

Countries

India

Contacts

Public ContactVijoy Kumar Jha

COMMAND HOSPITAL AIR FORCE BANGALORE

vkjhamd@gmail.com7330752528

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026